Our Research Publications
Updated November 2023
Pagination
- Previous page
- Page 8
- Next page
Title | Authors | Year | Journal Sort descending | Link to Article | Intended Audience | Purpose |
---|---|---|---|---|---|---|
How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry | Patriquin CJ, Kiss T, Caplan S, Chin-Yee I, Grewal K, Grossman J, Larratt L, Marceau D, Nevill T, Sutherland DR, Wells RA, Leber B | 2019 | Eur J Haematol | View How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry | Researchers | Clinical research |
Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia | Lin HX, Sjaarda J, Dyck J, Stringer R, Hillis C, Harvey M, Carter R, Ainsworth P, Leber B, Pare G, Sadikovic B | 2016 | Eur J Haematol | View Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia | Researchers | Clinical research |
Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders | Olasupo OO, Haddix C, Nakar C, Maahs J, Greist A, Ghafoor A, Donfield SM, Iorio A, Shapiro AD | 2022 | Eur J Haematol | View Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders | Health care providers | Benchmarking and standard setting |
The importance of haemophilia treatment centre administrators in patient care | Almonte T, Decker K, Seroski W, Walker I, Webert K, Bos C, Strike K, Waterhouse L, Goldsmith R, Chan AK | 2012 | Haemophilia | View The importance of haemophilia treatment centre administrators in patient care | Health care providers | Other |
Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company | Hay CRM, Shima M, Makris M, Jiménez-Yuste V, Oldenburg J, Fischer K, Iorio A, Skinner MW, Santagostino E, von Mackensen S, Kessler CM | 2020 | Haemophilia | View Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company | Researchers | Clinical research |
Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls | Mannucci PM, Nobili A, Marchesini E, Oliovecchio E, Cortesi L, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Peyvandi F, Iorio A | 2018 | Haemophilia | View Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls | Health care providers | Clinical research |
Exploring some intersections between pharmacokinetics, factor VIII measurement and human morphometrics - impact of recent advances in haemophilia study design on our understanding of optimal haemophilia treatment | Iorio A, Edginton AN | 2017 | Haemophilia | View Exploring some intersections between pharmacokinetics, factor VIII measurement and human morphometrics - impact of recent advances in haemophilia study design on our understanding of optimal haemophilia treatment | Researchers | Clinical research |
Point of care ultrasound in haemophilia: Building a strong foundation for clinical implementation | Lawson W, Uy M, Strike K, Iorio A, Stein N, Koziol L, Chan A | 2017 | Haemophilia | View Point of care ultrasound in haemophilia: Building a strong foundation for clinical implementation | Health care providers | Clinical research |
Emicizumab state-of-the-art update | Mahlangu J, Iorio A, Kenet G | 2022 | Haemophilia | View Emicizumab state-of-the-art update | Health care providers | Clinical research |
Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics | Nummi V, Lehtinen AE, Iorio A, Szanto T, Lassila R | 2022 | Haemophilia | View Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics | Researchers | Clinical research |
Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project | Iorio A, Skinner MW, Clearfield E, Messner D, Pierce GF, Witkop M, Tunis S | 2018 | Haemophilia | View Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project | Health care providers | Clinical research |
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A | Astermark J, Olsson A, Chelle P, Täckström K, Walger M, Magnusson M, Iorio A | 2021 | Haemophilia | View Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A | Researchers | Clinical research |
Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population | Marchesini E, Oliovecchio E, Coppola A, Santagostino E, Radossi P, Castaman G, Valdre L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Iorio A, Mannucci PM | 2018 | Haemophilia | View Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population | Health care providers | Clinical research |
A brief survey of clinicians' perceptions of parent preferences for involvement in obstetrical and perinatal management decisions in haemophilia | Lucier KJ, Movilla RV, Parvizian MK, Siddiqui R, Gabriele EH, Bourque M, MacIsaac J, Moorehead PC, Chan AK, Heddle NM, Lane SJ | 2018 | Haemophilia | View A brief survey of clinicians' perceptions of parent preferences for involvement in obstetrical and perinatal management decisions in haemophilia | Health care providers | Clinical research |
Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study | Lane SJ, Sholapur NS, Yeung CH, Iorio A, Heddle NM, Sholzberg M, Pai M | 2016 | Haemophilia | View Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study | Health care providers | Other |
Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement | Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, Negrier C, Oldenburg J, Reininger A, Rodriguez-Merchan C, Spannagl M, Valentino LA, Young G, Steinitz-Trost KN, Gringeri A | 2017 | Haemophilia | View Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement | Health care providers | Clinical research |
A systematic review of definitions and reporting of bleeding outcome measures in haemophilia | Chai-Adisaksopha C, Hillis C, Thabane L, Iorio A | 2015 | Haemophilia | View A systematic review of definitions and reporting of bleeding outcome measures in haemophilia | Health care providers | Clinical research |
Patterns of joint damage in severe haemophilia A treated with prophylaxis | Goren R, Pullenayegum E, Blanchette VS, Dover S, Carcao M, Israels SJ, Chan A, Rivard GE, Steele M, Cloutier S, Klaassen RJ, Sinha R, Price VE, Laferriere N, Paradis E, Wu JK, Feldman BM | 2021 | Haemophilia | View Patterns of joint damage in severe haemophilia A treated with prophylaxis | Health care providers | Clinical research |
First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System | Traore AN, Chan AKC, Webert KE, Heddle N, Ritchie B, St-Louis J, Teitel J, Lillicrap D, Iorio A, Walker I | 2014 | Haemophilia | View First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System | Health care providers | Clinical research |
Sexual issues in people with haemophilia: Awareness and strategies for overcoming communication barriers | Blamey G, Van Tassel B, Sagermann E, Stain AM, Waterhouse L, Iorio A | 2022 | Haemophilia | View Sexual issues in people with haemophilia: Awareness and strategies for overcoming communication barriers | Researchers | Ethical, legal and social implications research |
What should men living with haemophilia need to know? The perspectives of Canadian men with haemophilia | Arnold E, Lane S, Webert KE, Chan A, Walker I, Tufts J, Rubin S, Poon MC, Heddle NM | 2014 | Haemophilia | View What should men living with haemophilia need to know? The perspectives of Canadian men with haemophilia | Health care providers | Other |
Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study | Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ | 2017 | Haemophilia | View Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study | Researchers | Clinical research |
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature | Iorio A, Königs C, Reding MT, Rotellini D, Skinner MW, Mancuso ME, Berntorp E | 2023 | Haemophilia | View Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature | Health care providers | Clinical research |
What should men living with severe haemophilia need to know? The perspectives of Canadian haemophilia health care providers | Lane S, Arnold E, Webert KE, Chan A, Walker I, Heddle NM | 2013 | Haemophilia | View What should men living with severe haemophilia need to know? The perspectives of Canadian haemophilia health care providers | Health care providers | Other |
Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes | Pierce GF, Iorio A | 2018 | Haemophilia | View Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes | Health care providers | New or improved product or process |
Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes | Sun H, Yang M, Poon M-C, Lee A, Robinson KS, Sholzberg M, Wu J, Iorio A, Blanchette V, Carcao M, Klaassen RJ, Jackson S | 2021 | Haemophilia | View Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes | Researchers | Clinical research |
Switching to extended half-life products in Canada - preliminary data | Keepanasseril A, Stoffman J, Bouskill V, Carcao M, Iorio A, Jackson S | 2017 | Haemophilia | View Switching to extended half-life products in Canada - preliminary data | Health care providers | Clinical research |
Test-retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains | Chai-Adisaksopha C, Skinner MW, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker J, Thabane L, Crowther MA, Iorio A | 2019 | Haemophilia | View Test-retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains | Researchers | Clinical research |
Treatment decision-making among Canadian youth with severe haemophilia: a qualitative approach | Lane SJ, Walker I, Chan AK, Heddle NM, Poon MC, Minuk L, Jardine L, Arnold E, Sholapur N, Webert KE | 2015 | Haemophilia | View Treatment decision-making among Canadian youth with severe haemophilia: a qualitative approach | Health care providers | Clinical research |
Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time | Stonebraker JS, O'Mahony B, Noone D, Iorio A | 2021 | Haemophilia | View Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time | Researchers | Benchmarking and standard setting |
Evaluation of the sexual health in people living with hemophilia | Germini F, Chai-Adisaksopha C, Pete D, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker JS, Thabane L, Crowther MA, Skinner MW, Iorio A | 2021 | Haemophilia | View Evaluation of the sexual health in people living with hemophilia | Researchers | Clinical research |
A case of vertical transmission of Chagas Disease contracted via blood transfusion in Canada | Fearon MA, Scalia V, Huang M, Dines I, Ndao M | 2013 | Can J Infect Dis Med Microbiol | View A case of vertical transmission of Chagas Disease contracted via blood transfusion in Canada | Health care providers | Clinical research |
Risk-based decision making in transfusion medicine | Leach Bennett J, Devine DV | 2018 | Vox Sang | View Risk-based decision making in transfusion medicine | Researchers | New or improved product or process |
Human T-cell lymphotropic virus: A simulation model to estimate residual risk with universal leucoreduction and testing strategies in Canada | O'Brien SF, Yi Q-L, Goldman M, Grégoire Y, Delage G | 2018 | Vox Sang | View Human T-cell lymphotropic virus: A simulation model to estimate residual risk with universal leucoreduction and testing strategies in Canada | Researchers | New or improved product or process |
Whole blood donor return rates after deferral for tattooing or body piercing—Survey across blood donation services: The BEST collaborative study | Quee F, O'Brien SF, Prinsze F, Steele WR, Grégoire Y, Cutajar A, Wendel S, Compernolle V, Goldman M, van den Hurk K, Biomedical Excellence for Safer Transfusion Collaborative | 2022 | Vox Sang | View Whole blood donor return rates after deferral for tattooing or body piercing—Survey across blood donation services: The BEST collaborative study | Blood operators | Benchmarking and standard setting |
Lipoprotein enrichment in orange insoluble particulate matter reproducibly appearing in cryoprecipitate | Sheffield WP, Bhakta V, Trigatti B, Jenkins C | 2011 | Vox Sang | View Lipoprotein enrichment in orange insoluble particulate matter reproducibly appearing in cryoprecipitate | Blood operators | Basic research |
The effect of processing method on the in vitro characteristics of red blood cell products | Hansen AL, Kurach JDR, Turner TR, Jenkins C, Busch MP, Norris PJ, Dugger J, Tomasulo PA, Devine DV, Acker JP | 2015 | Vox Sang | View The effect of processing method on the in vitro characteristics of red blood cell products | Researchers | Basic research |
Vox Sanguinis International Forum on platelet cryopreservation | Cohn CS, Dumont LJ, Lozano M, Marks DC, Johnson L, Ismay S, Bondar N, T'Sas F, Yokoyama APH, Kutner JM, Acker JP, Bohonek M, Sailliol A, Martinaud C, Poglod R, Antoniewicz-Papis J, Lachert E, Pun PBL, Lu J, Cid J, Guijarro F, Puig L, Gerber B, Alberio L, Schanz U, Buser A, Noorman F, Zoodsma M, van der Meer PF, de Korte D, Wagner S, O'Neill M | 2017 | Vox Sang | View Vox Sanguinis International Forum on platelet cryopreservation | Blood operators | New or improved product or process |
Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities | Al-Riyami AZ, Schäfer R, van den Berg K, Bloch EM, Estcourt LJ, Goel R, Hindawi S, Josephson CD, Land K, McQuilten ZK, Spitalnik SL, Wood EM, Devine DV, So-Osman C | 2020 | Vox Sang | View Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities | Researchers | Clinical research |
Filariasis and transfusion-associated risk: a literature review | Drews SJ, Spencer BR, Wendel S, Bloch EM, International Society of Blood Transfusion TTID Working Party Parasite Subgroup | 2021 | Vox Sang | View Filariasis and transfusion-associated risk: a literature review | Health care providers | Clinical research |
Vox Sanguinis International Forum on Mitigation Strategies to Prevent Faint and Pre-faint Adverse Reactions in Whole Blood Donors: Summary | Goldman M, Townsend M, Magnussen K, Lozano M, Nissen-Meyer LS, Lee CK, Leung JN, Takanashi M, McKay J, Kvist M, Robitaille N, Deschênes J, Di Angelantonio E, McMahon A, Roberts D, Maghsudlu M, Castrén J, Tiberghien P, Woimant G, Morel P, Kamel H, Bravo M, Shinhar E, Gendelman V, Raz H, Wendel S, Fachini R, Quee F, van den Hurk K, Wiersum J, Grima K, Speedy J, Bruun M, Dunbar N | 2021 | Vox Sang | View Vox Sanguinis International Forum on Mitigation Strategies to Prevent Faint and Pre-faint Adverse Reactions in Whole Blood Donors: Summary | Health care providers | Benchmarking and standard setting |
Early and out-of-hospital use of COVID-19 convalescent plasma: An international assessment of utilization and feasibility | Al-Riyami AZ, Estcourt L, Rahimi-Levene N, Bloch EM, Goel R, Tiberghien P, Thibert J-B, Bruun MT, Devine DV, Gammon RR, Wendel S, Toungouz Nevessignsky M, Grubovic Rastvorceva RM, Oreh A, Romon I, van den Berg K, Kitazawa J, Patidar G, So-Osman C, Wood EM, the ISBT COVID-19 Convalescent Plasma Working Group | 2022 | Vox Sang | View Early and out-of-hospital use of COVID-19 convalescent plasma: An international assessment of utilization and feasibility | Health care providers | Clinical research |
Report on the 19th International Society of Blood Transfusion Platelet Immunology Workshop 2018 | Lewin A, Al Khan S, Beaudin L, Meilleur L, Clarke G, Richard L | 2020 | Vox Sang | View Report on the 19th International Society of Blood Transfusion Platelet Immunology Workshop 2018 | Health care providers | Benchmarking and standard setting |
Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: Standards of care | Lieberman L, Devine DV, Reesink HW, Panzer S, Wong J, Raison T, Benson S, Pink J, Leitner GC, Horvath M, Compernolle V, Scuracchio PSP, Wendel S, Delage G, Nahirniak S, Dongfu X, Krusius T, Juvonen E, Sainio S, Cazenave JP, Guntz P, Kientz D, Andreu G, Morel P, Seifried E, Hourfar K, Lin CK, O'Riordan J, Raspollini E, Villa S, Rebulla P, Flanagan P, Teo D, Lam S, Ang AL, Lozano M, Sauleda S, Cid J, Perreira A, Ekermo B, Niederhauser C, Waldvogel S, Fontana S, Desborough MJ, Pawson R, Li M, Kamel H, Busch M, Qu L, Triulzi D | 2014 | Vox Sang | View Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: Standards of care | Blood operators | Benchmarking and standard setting |
Standardization of CD62P measurement: results of an international comparative study | Levin E, Serrano K, Devine DV, for the Biomedical Excellence for Safer Transfusion Collaborative | 2013 | Vox Sang | View Standardization of CD62P measurement: results of an international comparative study | Blood operators | Benchmarking and standard setting |
The use of the electronic (computer) cross-match | Reesink HW, Davis K, Wong J, Schwartz DW, Mayr WR, Devine DV, Georgsen J, Chiaroni J, Ferrera V, Roubinet F, Lin CK, O'Donovan B, Fitzgerald JM, Raspollini E, Villa S, Rebulla P, Makino S, Gounder D, Safwenberg J, Murphy MF, Staves J, Milkins C, Mercado TC, Illoh OC, Panzer S | 2013 | Vox Sang | View The use of the electronic (computer) cross-match | Blood operators | Benchmarking and standard setting |
Transfusion-associated circulatory overload prevention: a retrospective observational study of diuretic use | Lin Y, Cohen R, Armali C, Callum J, Cserti-Gazdewich C, Lieberman L, Pendergrast J | 2018 | Vox Sang | View Transfusion-associated circulatory overload prevention: a retrospective observational study of diuretic use | Researchers | Clinical research |
Designing the blood supply chain: how much, how and where? | Osorio AF, Brailsford SC, Smith HK, Blake J | 2018 | Vox Sang | View Designing the blood supply chain: how much, how and where? | Other | New or improved product or process |
Trends in platelet distributions from 2008 to 2017: a survey of twelve national and regional blood collectors | Yazer MH, Shaz B, Seheult JN, Apelseth TO, de Korte D, Devin G, Devine D, Doncaster C, Field S, Flanagan P, Huet J, Mendrone Jr A, O’Brien C, Pink J, Rashleigh M, Shinar E, Takanashi M, Tian E, Tiberghien P, van den Berg K, Schmitt C | 2020 | Vox Sang | View Trends in platelet distributions from 2008 to 2017: a survey of twelve national and regional blood collectors | Blood operators | Benchmarking and standard setting |
International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Responses | Al-Riyami AZ, Burnouf T, Yazer M, Triulzi D, Kuma? LT, Sa?dur L, Pelit NB, Bazin R, Hindawi SI, Badawi MA, Patidar GK, Pandey HC, Chaurasia R, Fachini RM, Scuracchio P, Wendel S, Ang AL, Ong KH, Young P, Ihalainen J, Vierikko A, Qiu Y, Yang R, Xu H, Rahimi-Levene N, Shinar E, Izak M, Gonzalez CA, Ferrari DM, Cini PV, Aditya RN, Sharma RR, Sachdev S, Hans R, Lamba DS, Nissen-Meyer LSH, Devine DV, Lee CK, Leung JN-S, Hung IFN, Tiberghien P, Gallian P, Morel P, Al Maamari K, Al-Hinai Z, Vrielink H, So-Osman C, De Angelis V, Berti P, Ostuni A, Marano G, Nevessignsky MT, El Ekiaby M, Daly J, Hoad V, Kim S, van den Berg K, Vermeulen M, Glatt TN, Schäfer R, Reik R, Gammon R, Lopez M, Estcourt L, MacLennan S, Roberts D, Louw V, Dunbar N | 2021 | Vox Sang | View International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Responses | Researchers | Clinical research |